Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Interest Coverage No Debt
GEVA's Interest Coverage is ranked higher than
92% of the 364 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GEVA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GEVA' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: No Debt
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
» GEVA's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2014

GEVA Guru Trades in Q3 2014

Jim Simons 26,200 sh (New)
Columbia Wanger 3,927,006 sh (+11.53%)
» More
Q4 2014

GEVA Guru Trades in Q4 2014

Jim Simons Sold Out
Columbia Wanger 3,847,094 sh (-2.03%)
» More
Q1 2015

GEVA Guru Trades in Q1 2015

Columbia Wanger 3,245,542 sh (-15.64%)
» More
Q2 2015

GEVA Guru Trades in Q2 2015

Columbia Wanger Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:JAZZ, OTCPK:GMXAY, NAS:ALKS, NAS:MDVN, NAS:SGEN, NAS:ALNY, NAS:UTHR, OTCPK:SBMFF, NAS:ANAC, NAS:TSRO, NAS:ACAD, NAS:TECH, NAS:ICPT, OTCPK:BTGGF, NAS:IONS, OTCPK:UCBJY, NAS:JUNO, OTCPK:NVZMY, NAS:CBPO, NYSE:XON » details
Traded in other countries:TMS1.Germany,


Synageva BioPharma Corp is incorporated in Delaware in 1993. On November 2, 2011, Trimeris, Inc., a Delaware corporation closed a merger transaction, Reverse Merger with Synageva BioPharma Corp., Pursuant to the Merger Agreement, Private Synageva became a wholly owned subsidiary of Trimeris. As a Reverse Merger, Trimeris changed its name to Synageva BioPharma Corp. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The Company has several proteins therapeutic in its pipeline, including enzyme replacement therapies for lysosomal storage diseases (LSDs) and protein therapeutic programs for other rare diseases that are at the stage of preclinical development. Its program, sebelipase alfa is a recombinant human lysosomal acid lipase deficiency (LAL Deficiency), currently evaluating in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. LAL Deficiency is rare autosomal recessive LSD characterized by decreased LAL enzyme activity leading to intracellular accumulation of lipids. This disease leads to medical complications with significant morbidity and early mortality. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants. The Company has not yet received approval to market this product and is not currently commercializing any other products. Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing Phase 3 Trial of Sebelipase Alfa in Children and Adults with LAL Deficiency. It is also pursuing a development strategy for sebelipase alfa to assess safety and tolerability in a broad population of patients, including infants, children, and adults, and to demonstrate efficacy, safety and tolerability of sebelipase alfa in the treatment of LAL Deficiency. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $5.83
EPS (TTM) $ -6.34
Short Percentage of Float15.13%
52-Week Range $60.19 - 239.20
Shares Outstanding (Mil)37.15

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec15 Dec16 Dec17
Revenue (Mil $) 7 51 148
EPS ($) -6.75 -6.02 -4.37
EPS w/o NRI ($) -6.75 -6.02 -4.37
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for GEVA

Headlines

Articles On GuruFocus.com
Columbia Wanger Sells 22 Stakes in Second Quarter Aug 17 2015 
Alexion Acquiring Synageva For $8.4 Billion May 09 2015 
Wednesday Pre-Market Insights: GEVA, BRDR, MGI, NDLS, ZU May 06 2015 

More From Other Websites
Alexion gets EU approval for drug acquired in Synageva deal Sep 01 2015
Columbia Wanger Sells 22 Stakes in Second Quarter Aug 17 2015
Bluebird, Pacira Pharmaceuticals Excite Life Science Investors Aug 12 2015
MDGN: Efficacy of Target EPO Now Through 13 Months Aug 11 2015
Alexion Facing Big Costs, Guidance Disappoints Jul 30 2015
Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk Jul 27 2015
Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns Jul 10 2015
SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Jun 23 2015
The Only Way to Play Biotech Buyouts Jun 09 2015
Why These 4 Biotech Stocks Could Be the Next Buyout Targets May 07 2015
Rich Synageva M&A premium epitomizes appetite for orphan drugs May 06 2015
Alexion Pharma to pay $8.4 billion for Synageva BioPharma May 06 2015
Is Alexion Grossly Overpaying for Synageva? May 06 2015
Alexion Pharma to buy Synageva BioPharma for $8.4 bln May 06 2015
Synageva BioPharma reports 1Q loss Apr 29 2015
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY)... Mar 05 2015
Synageva BioPharma reports 4Q loss Feb 26 2015
New Year, New Biotech Stock Offerings -- Lots of 'Em Jan 05 2015
Biotech Bull Markets and Billion-Dollar Valuations Dec 23 2014
Synageva BioPharma beats 3Q profit forecasts Oct 31 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)